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Background Findings Findings Discussion
Postoperative nausea and vomiting remains a common and unpleasant 
side effect for patients following surgery. Uncontrolled PONV can result 
in prolonged hospital stays, unanticipated hospital readmissions, and 
decreased patient satisfaction. The Apfel score identifies and counts 
independent risk factors for PONV; females, non-smokers, postoperative 
opioid use, and history of PONV or motion sickness. Rates of PONV 
increases as the number of risk factors increase. The primary 
intervention to decrease PONV is administration of prophylactic 
antiemetics. Research supports the use of combination antiemetic 
therapy for patients with a high number of risk factors. 
The purpose of this evidence based practice (EBP) project was to report 
the rate of PONV among surgical patients who received general 
anesthesia, comparing combination prophylactic antiemetics of 
ondansetron and dexamethasone to single antiemetic administration.
Comparison of Ondansetron, Dexamethasone, and its Combination in the Prevention 
of Postoperative Nausea and Vomiting 
Alina Palanchuk BSN, RN, SRNA; Kenn Daratha PhD
Gonzaga University and Providence Sacred Heart Medical Center
References
Methods
• A retrospective, EBP project was conducted at Providence Sacred 
Heart Medical Center (PSHMC) in Spokane, WA.
• Permission was obtained by the facility and exemption determination 
was granted by the IRB.
• Patient data was securely extracted and stored in a HIPPA compliant 
REDCap database. Patient data was fully de-identified. Data 
extraction included all surgeries in the 2018 calendar year. 
• Inclusion criteria: Adult patients > 18 years old, non-emergent surgery, 
general anesthesia (ETT, LMA) using volatile inhalational agents or 
total intravenous anesthesia.
• Exclusion criteria: Pediatric, obstetric, emergency surgery, direct 
admission to ICU. 
• PONV outcome determined by nursing documentation of PONV scale, 
intervention, reassessment or signs/symptoms or administration of 
antiemetic medication. 
• Descriptive data analysis completed and stratified by the number of 
Apfel risk factors. Independent risk factors determined using binary 
logistic regression. Level of significance set at 0.05. 
CONCLUSION
When controlling for all literature reported PONV risk factors, this EBP 
project demonstrated that the odds of  PONV reduction were similar for 
combination and individual antiemetic therapy. Similar to current 
research evidence, the identified independent risk factors for PONV were 
female gender, history of PONV or motion sickness, postoperative opioid 
administration, younger age, high risk procedures, and increased case 
duration. Non-smoking status and nitrous oxide use were not observed 
to be independent risk factors. 
As Apfel reported, this project similarly reported an increase rate in 
PONV as the number of PONV risk factors increased. The observed risk 
of PONV decreased among patients with at least one Apfel risk factor 
following prophylactic antiemetic administration. 
IMPLICATIONS
Practice at PSHMC is demonstrating that combination prophylactic 
treatment is being used for patients with higher PONV risk factors. 
Practice is following current research evidence. Anesthetists should 
continue to tailor prophylactic antiemetic administration to patients based 
on presenting risk factors. 
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Figure 1: PONV by Time Period Followed
Table 3: Incidence of PONV by Apfel Risk FactorTable 1: Baseline Demographic and Clinical Characteristics
A significant result is a P-value <0.05
(N=12,193) %
Apfel risk factors:
Female gender 7,010 57%
Non-smoker 7,831 64%
Postoperative opioids 6,827 56%
History of PONV/motion sickness 1,772 15%
Gynecologic procedures 981 8%
Laparoscopic procedures 1,276 10%
Cholecystectomy procedures 219 2%
Anesthesia type:
Inhalational agent 11,650 96%
Total intravenous anesthesia 543 4%
Mean SD
Age (years) 58 16
# Apfel risk factors 2 1
Median IQR
Duration of surgery (min) 102 64-152
Duration of nitrous oxide (min) 19 9-33
Variable OR 95% CI P Value
Female gender 1.63 1.48-1.80 <0.001
Non-smoker 1.08 0.99-1.19 0.09
Postoperative opioids 1.80 1.63-1.98 <0.001
History of PONV/ motion sickness 1.32 1.17-1.49 <0.001
Age 0.93 0.90-0.95 <0.001
High risk procedures* 1.72 1.53-1.93 <0.001
Case duration 1.23 1.19-1.26 <0.001
Inhalational agent use 0.90 0.72-1.13 0.36
Nitrous oxide use 1.00 0.90-1.11 0.95
Antiemetic administered:
Ondansetron 0.69 0.57-0.83 <0.001
Dexamethasone 0.69 0.53-0.88 0.003
Ondansetron & Dexamethasone 0.64 0.54-0.76 <0.001
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None (Predicted) 83 751 834 10%
Ondansetron 35 288 323 11% 1.09 0.75-1.58 0.65
Dexamethasone 5 55 60 8% 0.84 0.35-1.99 0.69
Ondansetron & Dexamethasone 46 405 451 10% 1.02 0.73-1.40 0.89





None (Predicted) 617 2322 2939 21%
Ondansetron 140 818 958 15% 0.70 0.59-0.82 <0.0001
Dexamethasone 26 143 169 15% 0.73 0.51-1.05 0.09
Ondansetron & Dexamethasone 273 1539 1812 15% 0.72 0.63-0.82 <0.0001





None (Predicted) 1581 2474 4055 39%
Ondansetron 197 728 925 21% 0.55 0.48-0.62 <0.0001
Dexamethasone 45 185 230 20% 0.50 0.38-0.65 <0.0001
Ondansetron & Dexamethasone 672 2228 2900 23% 0.59 0.55-0.64 <0.0001





None (Predicted) 1670 1068 2738 61%
Ondansetron 117 304 421 28% 0.45 0.40-0.53 <0.0001
Dexamethasone 54 85 139 39% 0.64 0.52-0.79 <0.0001
Ondansetron & Dexamethasone 645 1533 2178 30% 0.48 0.45-0.52 <0.0001





None (Predicted) 532 142 674 79%
Ondansetron 27 55 82 33% 0.42 0.31-0.57 <0.0001
Dexamethasone 6 19 25 24% 0.30 0.15-0.61 0.0008
Ondansetron & Dexamethasone 221 346 567 39% 0.49 0.44-0.55 <0.0001
*High risk procedures include laparoscopic, gynecological, and cholecystectomy procedures
